| Recruiting | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors NCT06819215 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study of ESG401 in Adults With Solid Tumors NCT04892342 | Shanghai Escugen Biotechnology Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Ne NCT04915755 | GlaxoSmithKline | Phase 3 |
| Terminated | Early Rehabilitation for Breast Cancer - A Randomized Control Trial NCT04777786 | University of South Carolina | N/A |
| Unknown | Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulatin NCT05814224 | Centro di Riferimento Oncologico - Aviano | N/A |
| Completed | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With NCT03329937 | Tesaro, Inc. | Phase 1 |
| Terminated | Pre- Versus Postoperative Accelerated Partial Breast Irradiation NCT02913729 | The Netherlands Cancer Institute | N/A |
| Unknown | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer NCT03273595 | Xijing Hospital | Phase 2 |
| Terminated | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metas NCT02213042 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patient NCT01782651 | GlaxoSmithKline | — |
| Terminated | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Bre NCT01905592 | Tesaro, Inc. | Phase 3 |
| Completed | Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer NCT02063893 | Fuda Cancer Hospital, Guangzhou | — |
| Completed | A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid NCT01815294 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer NCT01476111 | GlaxoSmithKline | — |
| Terminated | Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer NCT01498588 | Emory University | Phase 2 |
| Withdrawn | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy i NCT01137994 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzuma NCT01160211 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-p NCT01220128 | GlaxoSmithKline | Phase 2 |
| Withdrawn | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer NCT01205217 | GlaxoSmithKline | Phase 2 |
| Completed | Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC NCT01138046 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer NCT01118624 | Acrotech Biopharma Inc. | Phase 2 |
| Completed | A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib NCT00996762 | GlaxoSmithKline | Phase 1 |
| Completed | Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer NCT01271738 | Emory University | N/A |
| Completed | Treatment With Pazopanib for Neoadjuvant Breast Cancer NCT00849472 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Sub NCT00849329 | GlaxoSmithKline | Phase 1 |
| Completed | A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 NCT00821054 | GlaxoSmithKline | Phase 1 |
| Completed | Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents NCT00790816 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tum NCT00722293 | GlaxoSmithKline | Phase 1 |
| Completed | Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC NCT00709761 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects NCT00709618 | GlaxoSmithKline | Phase 2 |
| Terminated | Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGF NCT00820924 | GlaxoSmithKline | Phase 2 |
| Completed | Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Bre NCT00650910 | GlaxoSmithKline | Phase 1 |
| Terminated | Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocri NCT00661531 | Georgetown University | Phase 2 |
| Completed | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study NCT00553358 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer NCT00558103 | GlaxoSmithKline | Phase 2 |
| Terminated | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer NCT00479856 | GlaxoSmithKline | Phase 2 |
| Completed | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. NCT00524303 | GlaxoSmithKline | Phase 2 |
| Terminated | Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China NCT00508274 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer NCT00477464 | GlaxoSmithKline | Phase 2 |
| Completed | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D NCT00490139 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Brain Metastases In ErbB2-Positive Breast Cancer NCT00437073 | GlaxoSmithKline | Phase 2 |
| Completed | Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer NCT00422903 | GlaxoSmithKline | Phase 2 |
| Completed | Lapatinib and Bevacizumab for Metastatic Breast Cancer NCT00444535 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Ca NCT00367471 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer NCT00429299 | GlaxoSmithKline | Phase 2 |
| Completed | Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer NCT00374322 | GlaxoSmithKline | Phase 3 |
| Completed | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer NCT00347919 | GlaxoSmithKline | Phase 2 |
| Approved For Marketing | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer NCT00338247 | Novartis | — |
| Completed | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer NCT00356811 | GlaxoSmithKline | Phase 2 |
| Completed | Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), NCT00388076 | GlaxoSmithKline | Phase 1 |
| Completed | GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer NCT00371488 | GlaxoSmithKline | Phase 1 |
| Completed | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 NCT00281658 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib NCT00272987 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer NCT00263588 | Novartis Pharmaceuticals | Phase 2 |
| Completed | GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer NCT00320411 | GlaxoSmithKline | Phase 2 |
| Completed | To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients NCT00258050 | GlaxoSmithKline | Phase 1 |
| Completed | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastat NCT00320385 | GlaxoSmithKline | Phase 3 |
| Terminated | GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast NCT00251433 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Canc NCT00111787 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer NCT00140738 | GlaxoSmithKline | Phase 1 |
| Completed | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer NCT00105950 | GlaxoSmithKline | Phase 2 |
| Completed | Rollover Study Of Lapatinib In Cancer Patients NCT00169533 | GlaxoSmithKline | Phase 1 |
| Completed | Study Of Ispinesib In Subjects With Breast Cancer NCT00089973 | GlaxoSmithKline | Phase 2 |
| Completed | GW572016 In Patients With Advanced Or Metastatic Breast Cancer NCT00462956 | GlaxoSmithKline | Phase 1 |
| Completed | Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Bre NCT00359190 | GlaxoSmithKline | Phase 1 |
| Completed | Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer NCT00089999 | GlaxoSmithKline | Phase 2 |
| Completed | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Bre NCT00075270 | GlaxoSmithKline | Phase 3 |
| Completed | GW572016 For Treatment Of Refractory Metastatic Breast Cancer NCT00062686 | GlaxoSmithKline | Phase 2 |
| Completed | Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) NCT00148902 | GlaxoSmithKline | Phase 1 |
| Completed | A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer NCT00058526 | GlaxoSmithKline | Phase 1 |
| Completed | Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. NCT00051103 | GlaxoSmithKline | Phase 2 |